@article{cd5845e03a434a079ea3bb6e1f502e79,
title = "The respiratory syncytial virus vaccine landscape: lessons from the graveyard and promising candidates",
abstract = "The global burden of disease caused by respiratory syncytial virus (RSV) is increasingly recognised, not only in infants, but also in older adults (aged ≥65 years). Advances in knowledge of the structural biology of the RSV surface fusion glycoprotein have revolutionised RSV vaccine development by providing a new target for preventive interventions. The RSV vaccine landscape has rapidly expanded to include 19 vaccine candidates and monoclonal antibodies (mAbs) in clinical trials, reflecting the urgency of reducing this global health problem and hence the prioritisation of RSV vaccine development. The candidates include mAbs and vaccines using four approaches: (1) particle-based, (2) live-attenuated or chimeric, (3) subunit, (4) vector-based. Late-phase RSV vaccine trial failures highlight gaps in knowledge regarding immunological protection and provide lessons for future development. In this Review, we highlight promising new approaches for RSV vaccine design and provide a comprehensive overview of RSV vaccine candidates and mAbs in clinical development to prevent one of the most common and severe infectious diseases in young children and older adults worldwide.",
author = "{Respiratory Syncytial Virus Network (ReSViNET) Foundation} and Mazur, {Natalie I.} and Deborah Higgins and Nunes, {Marta C.} and Melero, {Jos{\'e} A.} and Langedijk, {Annefleur C.} and Nicole Horsley and Buchholz, {Ursula J.} and Openshaw, {Peter J.} and McLellan, {Jason S.} and Englund, {Janet A.} and Asuncion Mejias and Karron, {Ruth A.} and Sim{\~o}es, {Eric AF} and Ivana Knezevic and Octavio Ramilo and Piedra, {Pedro A.} and Chu, {Helen Y.} and Falsey, {Ann R.} and Harish Nair and Leyla Kragten-Tabatabaie and Anne Greenough and Eugenio Baraldi and Papadopoulos, {Nikolaos G.} and Johan Vekemans and Polack, {Fernando P.} and Mair Powell and Ashish Satav and Walsh, {Edward E.} and Stein, {Renato T.} and Graham, {Barney S.} and Bont, {Louis J.}",
note = "Funding Information: HYC's institution receives research funding from Sanofi-Pasteur and Novavax. UJB's work was funded by the Intramural Research Program, NIAID, NIH; Work of the RNA Viruses Section of the Laboratory of Infectious Diseases, Division of Intramural Research, NIAID, NIH was funded in part by a CRADA with Sanofi Pasteur, outside the submitted work. UJB is an inventor on a patent, with royalties paid by Sanofi Pasteur. JAE's institution receives research funding from Novavax, Medimmune, Alios, and GlaxoSmithKline. BSG has pending patent applications for candidate subunit RSV F vaccines. ARF reports grants and personal fees from Gilead, personal fees from Sanofi Pasteur, grants from Janssen, and Medimmune, outside the submitted work. AM reports grants from NIH NIAID and NIH NICDH, grants and personal fees from Janssen, and personal fees from Abbvie, outside the submitted work. AG reports grants and other from Medimmune and Abbott, outside the submitted work. PAP reports grants and personal fees from Novavax, grants from Janssen and Gilead, grants and personal fees from Ablynx, personal fees from Merck, and grants from Virometic, outside the submitted work. PJO reports personal fees from Consultancy, grants from MRC, The EU, NIHR Biomedical Research Centre, MRC/GSK, Wellcome Trust, NIHR (HPRU), NIHR Senior Investigator, personal fees from European Respiratory Society, outside the submitted work; He is President of the British Society for Immunology. This is an unpaid appointment but travel and accommodation at some meetings is provided by the Society. OR reports grants from NIH NIAID, NIH NICDH, grants and personal fees from Janssen, personal fees from Abbvie, Pfizer, Merck, Johnson and Johnson, and Sanofi, outside the submitted work. OR reports grants from NIH NIAID and NIH NICDH, grants and personal fees from Janssen, personal fees from Abbvie, Pfizer, Merck, Johnson and Johnson and Sanofi, grants from the Bill & Melinda Gates Foundation, outside the submitted work. NGP reports personal fees from Novartis, Faes Farma, BIOMAY, HAL, Nutricia Research, Menarini, Novartis, MEDA, Abbvie, MSD, Omega Pharma and Danone outside the submitted work and grants from Menarini. MCN reports personal fees from Pfizer, and non-financial support from Sanofi Pasteur, outside the submitted work. JSM is an inventor on patent No. 9,738,689, Prefusion RSV F Proteins and Their Use with royalties paid. JAM reports grants from Plan Nacional I-D-i (Spain), during the conduct of the study. HN reports grants from the Bill & Melinda Gates Foundation, Innovative Medicines Initiative, and Sanofi, and non-financial support from MedImmune, outside the submitted work. FPP reports grants and personal fees from Janssen and Novavax, Inc, personal fees from Bavarian Nordic A/S, Pfizer, Sanofi, Regeneron, and Merck, during the conduct of the study. EEW reports other from Gilead Pharmaceuticals, Janssen Inc, Novavax, and Pfizer, outside the submitted work. EAFS reports grants from AstraZeneca and Regeneron, outside the submitted work. EB reports personal fees from Chiesi and Abbvie, outside the submitted work. LJB reports grants from AstraZeneca, AbbVie, Novavax, Janssen, and other from Bavaria Nordic and MabXience, during the conduct of the study. RAK reports grants from National Institutes of Health, and personal fees from Merck, outside the submitted work. The authors alone are responsible for the views expressed in this publication, which do not necessarily represent the decisions or the stated policy of any organisation, institution or agency. Publisher Copyright: {\textcopyright} 2018 World Health Organization. Published by Elsevier Ltd/Inc/BV. All rights reserved.",
year = "2018",
month = oct,
doi = "10.1016/S1473-3099(18)30292-5",
language = "English (US)",
volume = "18",
pages = "e295--e311",
journal = "The Lancet Infectious Diseases",
issn = "1473-3099",
publisher = "Lancet Publishing Group",
number = "10",
}